

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 17:39:33 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Billet, Courtney (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]
Subject: RE: for review: proposed responses for Italian media request

Nice Job. I have made one minor edit in the first response. Otherwise, it is ready to go. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6) >
Sent: Friday, February 14, 2020 12:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Billet, Courtney (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Subject: for review: proposed responses for Italian media request

Dr. Fauci –

This is not urgent for today. A reporter from the Italian health website Pazienti.it reached out to you directly with questions about coronavirus vaccine development. I have drafted proposed responses for your review attached and pasted below. I will send the final responses to the reporter attributed to you.

Coronavirus vaccine: when will it be available? What are the difficulties?

The National Institutes of Health is on track to test an experimental messenger RNA (mRNA) vaccine in a Phase 1 clinical trial this spring. This first phase of clinical testing will involve giving the vaccine to healthy adults in the United States to see if it is safe and if it can induce an immune response in recipients. It is important to realize that the development of investigational vaccines and the clinical testing to establish their safety and effectiveness takes time. A vaccine against the novel coronavirus will likely not be widely available for at least a year.